Jose Manuel Otero, Chief Operating Officer of Lexeo Therapeutics, Inc., filed a Form 4 on November 18, 2026, disclosing a sale of 1,285 shares of common stock on November 17, 2026, to cover tax obligations arising from the release of restricted stock units.

Key Highlights

  • Reporting person: Jose Manuel Otero, Chief Operating Officer of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)
  • Transaction: 1,285 shares of common stock disposed of (transaction code S) on November 17, 2026
  • Weighted average sale price: $3.26 per share, with individual trades ranging from $3.22 to $3.31
  • Purpose of sale: According to the filing, the transaction "represents a sale to cover tax obligations on the release of restricted stock units"
  • Beneficial ownership following transaction: 137,003 shares, held directly, including 93,432 restricted stock units

Otero's RSU Tax-Related Sale and Remaining Ownership at Lexeo Therapeutics

According to the Form 4 filed with the SEC on November 18, 2026, Jose Manuel Otero, the Chief Operating Officer of Lexeo Therapeutics, Inc., disposed of 1,285 shares of the company's common stock on November 17, 2026. The filing identifies the transaction code as "S" and states that the sale was made to cover tax obligations triggered by the vesting and release of restricted stock units (RSUs), not as a discretionary market sale.

The filing discloses that the transaction was executed across multiple trades at prices ranging from $3.22 to $3.31 per share. The price of $3.26 reported in the filing reflects the weighted average sale price across those trades. The filing further states that Otero "undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."

Following the reported transaction, Otero's direct beneficial ownership stands at 137,003 shares of common stock. The filing notes that this total includes 93,432 restricted stock units. All reported holdings are held directly. The Form 4 was signed by Youjin Choi as attorney-in-fact on November 18, 2026.

What Was Disclosed

Lexeo Therapeutics COO Jose Manuel Otero disclosed a sale of 1,285 shares of common stock on November 17, 2026, at a weighted average price of $3.26, solely to cover taxes on RSU vesting, leaving him with 137,003 shares beneficially owned directly.